Cargando…

First-Line Treatment with a Cyclin-Dependent Kinase 4/6 Inhibitor Plus an Aromatase Inhibitor for Metastatic Breast Cancer in Alberta

In this analysis, we describe population-based outcomes for first-line treatment with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) combined with an aromatase inhibitor (AI). All patients who were prescribed CDK4/6i + AI from January 2016 through June 2019 were included. Patient demographics, tu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Amaro, Carla P., Batra, Atul, Lupichuk, Sasha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293123/ https://www.ncbi.nlm.nih.gov/pubmed/34207443 http://dx.doi.org/10.3390/curroncol28030209

Ejemplares similares

Four Cycles of Docetaxel-Cyclophosphamide versus Anthracycline-Taxane as Adjuvant Chemotherapy for HER2-Negative, Axillary Lymph Node Negative Breast Cancer: A Real-World Comparison of Alberta Patients Treated 2008–2012
por: Hannouf, Malek, et al.
Publicado: (2021)

Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
por: Alvarado-Miranda, Alberto, et al.
Publicado: (2023)

The Renaissance of Cyclin Dependent Kinase Inhibitors
por: Ettl, Tobias, et al.
Publicado: (2022)

Aromatase inhibitor strategies in metastatic breast cancer
por: McArthur, Heather L, et al.
Publicado: (2010)

First-line endocrine treatment of breast cancer: aromatase inhibitor or antioestrogen?
por: Wong, Z-W, et al.
Publicado: (2004)

Real-World Effectiveness of Palbociclib Plus Aromatase Inhibitors in African American Patients With Metastatic Breast Cancer
por: Rugo, Hope S, et al.
Publicado: (2023)

Cyclin-dependent kinase inhibitors in malignant hematopoiesis
por: Schirripa, Alessia, et al.
Publicado: (2022)

Aromatase and Dual Aromatase-Steroid Sulfatase Inhibitors from the Letrozole and Vorozole Templates
por: Wood, Paul M, et al.
Publicado: (2011)

Identification of High-Affinity Inhibitors of Cyclin-Dependent Kinase 2 Towards Anticancer Therapy
por: Mohammad, Taj, et al.
Publicado: (2019)

Review of cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancer
por: Husinka, Lakyn, et al.
Publicado: (2020)

Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer
por: Giannone, Gaia, et al.
Publicado: (2019)

Inhibitors of Cyclin-Dependent Kinases: Types and Their Mechanism of Action
por: Łukasik, Paweł, et al.
Publicado: (2021)

Sequencing of aromatase inhibitors
por: Bertelli, G
Publicado: (2005)

Cyclin kinase inhibitors and interferons in lupus
por: Theofilopoulos, A
Publicado: (2003)

Four cycles of docetaxel and cyclophosphamide as adjuvant chemotherapy in node negative breast cancer: A real-world study
por: Batra, Atul, et al.
Publicado: (2020)

Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2022)

Genetic Status and Expression of the Cyclin‐dependent Kinase Inhibitors in Human Gastric Carcinoma Cell Lines
por: Akama, Yoshihiko, et al.
Publicado: (1996)

Silencing cyclin-dependent kinase inhibitor 3 inhibits the migration of breast cancer cell lines
por: Deng, Miao, et al.
Publicado: (2016)

Real-World Tumor Response of Palbociclib in Combination With an Aromatase Inhibitor as First-Line Therapy in Pre/Perimenopausal Women With Metastatic Breast Cancer
por: DeMichele, Angela, et al.
Publicado: (2023)

Characterising an aromatase inhibitor resistant breast cancer cell line
por: Harris, E, et al.
Publicado: (2012)

Progression after First-Line Cyclin-Dependent Kinase 4/6 Inhibitor Treatment: Analysis of Molecular Mechanisms and Clinical Data
por: Villa, Federica, et al.
Publicado: (2023)

Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management
por: Hyder, Tara, et al.
Publicado: (2021)

Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health Network
por: Law, Jeanna Wallenta, et al.
Publicado: (2022)

Pseudoprogression After Palbociclib with Aromatase Inhibitors Treatment in Metastatic Breast Cancer
por: Huang, Weiwei, et al.
Publicado: (2020)

Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy: Miniperspective
por: Sonawane, Yogesh A., et al.
Publicado: (2016)

Cyclin-Dependent Kinase Inhibitors Induce Apoptosis in Plant Cells
por: Strnad, M., et al.
Publicado: (2001)

Purine Inhibitors of Cyclin-Dependent Kinase and Their Apoptosis and Cytotoxicity Mechanisms
por: Strnad, M., et al.
Publicado: (2001)

Cyclin-dependent kinases and CDK inhibitors in virus-associated cancers
por: Tavakolian, Shaian, et al.
Publicado: (2020)

Bone loss and the aromatase inhibitors
por: Lester, J, et al.
Publicado: (2005)

Aromatase inhibitors in male sex
por: Singh, Santosh Kumar
Publicado: (2013)

Aromatase inhibitors in the treatment of endometriosis
por: Słopień, Radosław, et al.
Publicado: (2016)

Molecular Docking of Aromatase Inhibitors
por: Suvannang, Naravut, et al.
Publicado: (2011)

Aromatase Inhibitors in Erectile Dysfunction
por: Singh, Santosh
Publicado: (2021)

Long-term complete remission of metastatic breast cancer, induced by a steroidal aromatase inhibitor after failure of a non-steroidal aromatase inhibitor
por: Shioi, Yoshihiro, et al.
Publicado: (2014)

Synergism of Cyclin-Dependent Kinase Inhibitors with Camptothecin Derivatives in Small Cell Lung Cancer Cell Lines
por: Hamilton, Gerhard, et al.
Publicado: (2014)

[Retracted] Silencing cyclin‑dependent kinase inhibitor 3 inhibits the migration of breast cancer cell lines
por: Deng, Miao, et al.
Publicado: (2023)

Shared Decision-Making on Using a CDK4/6 Inhibitor plus an Aromatase Inhibitor for HR+/HER2− Metastatic Breast Cancer: A Podcast
por: Dong, Brian, et al.
Publicado: (2023)

A Polymorphism at the 3′-UTR Region of the Aromatase Gene Is Associated with the Efficacy of the Aromatase Inhibitor, Anastrozole, in Metastatic Breast Carcinoma
por: Liu, Lei, et al.
Publicado: (2013)

Safety of cyclin-dependent kinase4/6 inhibitor combined with palliative radiotherapy in patients with metastatic breast cancer
por: Kim, Kristine N., et al.
Publicado: (2021)

Adverse Cardiovascular Events Associated With Cyclin‐Dependent Kinase 4/6 Inhibitors in Patients With Metastatic Breast Cancer
por: Fradley, Michael G., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8d0rmrefh5hfuuf2hik7fhmolc